about
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several ne...
Read More
186.39
-3.49
(-1.84%)
6.7M
XNYS Volume
XNYS 15 Jul, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Abbvie Inc is on 25 Jul 2025 for the purpose of AbbVie Inc Second Quarter Earnings Results for 2025
See details
Low Financial Strength
Mid Valuation
Technically Neutral
Await Turnaround
These stocks are of poor quality, but mid-range financials and valuations. Their performance may improve based on financials, however our advise would be to be careful before buying these stocks.
View Similar
Embed DVM
AbbVie Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..